A noticeable growth can be seen in the year 2022 owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).
“Adrenoleukodystrophy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market.
Adrenoleukodystrophy: Disease Overview
Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands.
Know more about report offerings: https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight
Key Highlights: Adrenoleukodystrophy Pipeline
- The Adrenoleukodystrophy market is driven by key pharma players such as Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, and others are proactively focusing on advancing ALD pipeline, increasing prevalence, and increased R&D in the domain.
- A noticeable growth can be seen in the year 2022 owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).
Request for sample pages: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight
A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease overview and Adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces in-depth Adrenoleukodystrophy commercial assessment and clinical assessment of the Adrenoleukodystrophy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Read more: https://www.delveinsight.com/blog/adrenoleukodystrophy-market-size/
Table of Contents
1. Report Introduction
3. Adrenoleukodystrophy Current Treatment Patterns
4. Adrenoleukodystrophy DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Adrenoleukodystrophy Late Stage Products (Phase-III)
7. Adrenoleukodystrophy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Adrenoleukodystrophy Discontinued Products
13. Adrenoleukodystrophy Product Profiles
14. Adrenoleukodystrophy Key Companies
15. Adrenoleukodystrophy Key Products
16. Dormant and Discontinued Products
17. Adrenoleukodystrophy Unmet Needs
18. Adrenoleukodystrophy Future Perspectives
19. Adrenoleukodystrophy Analyst Review
21. Report Methodology
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States